These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 1979369)

  • 1. Preliminary report: protection of cynomolgus macaques against simian immunodeficiency virus by fixed infected-cell vaccine.
    Stott EJ; Chan WL; Mills KH; Page M; Taffs F; Cranage M; Greenaway P; Kitchin P
    Lancet; 1990 Dec 22-29; 336(8730):1538-41. PubMed ID: 1979369
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vaccination with the Conserved Caveolin-1 Binding Motif in Human Immunodeficiency Virus Type 1 Glycoprotein gp41 Delays the Onset of Viral Infection and Provides Partial Protection in Simian/Human Immunodeficiency Virus-Challenged Cynomolgus Macaques.
    Hovanessian AG; Soundaramourty C; Benferhat R; Le Grand R; Dereuddre-Bosquet N; Krust B; Estaquier J
    J Virol; 2018 Sep; 92(18):. PubMed ID: 29976675
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Live attenuated simian immunodeficiency virus prevents super-infection by cloned SIVmac251 in cynomolgus monkeys.
    Titti F; Sernicola L; Geraci A; Panzini G; Di Fabio S; Belli R; Monardo F; Borsetti A; Maggiorella MT; Koanga-Mogtomo M; Corrias F; Zamarchi R; Amadori A; Chieco-Bianchi L; Verani P
    J Gen Virol; 1997 Oct; 78 ( Pt 10)():2529-39. PubMed ID: 9349474
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The appearance of escape variants in vivo does not account for the failure of recombinant envelope vaccines to protect against simian immunodeficiency virus.
    Almond N; Jenkins A; Jones S; Arnold C; Silvera P; Kent K; Mills KHG; Stott EJ
    J Gen Virol; 1999 Sep; 80 ( Pt 9)():2375-2382. PubMed ID: 10501490
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunization of macaques with live simian human immunodeficiency virus (SHIV) vaccines conferred protection against AIDS induced by homologous and heterologous SHIVs and simian immunodeficiency virus.
    Kumar A; Mukherjee S; Shen J; Buch S; Li Z; Adany I; Liu Z; Zhuge W; Piatak M; Lifson J; McClure H; Narayan O
    Virology; 2002 Sep; 301(2):189-205. PubMed ID: 12359422
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vaccination of Macaques with DNA Followed by Adenoviral Vectors Encoding Simian Immunodeficiency Virus (SIV) Gag Alone Delays Infection by Repeated Mucosal Challenge with SIV.
    Almond N; Berry N; Stebbings R; Preston M; Ham C; Page M; Ferguson D; Rose N; Li B; Mee ET; Hassall M; Stahl-Hennig C; Athanasopoulos T; Papagatsias T; Herath S; Benlahrech A; Dickson G; Meiser A; Patterson S
    J Virol; 2019 Nov; 93(21):. PubMed ID: 31413132
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Temporal analyses of virus replication, immune responses, and efficacy in rhesus macaques immunized with a live, attenuated simian immunodeficiency virus vaccine.
    Connor RI; Montefiori DC; Binley JM; Moore JP; Bonhoeffer S; Gettie A; Fenamore EA; Sheridan KE; Ho DD; Dailey PJ; Marx PA
    J Virol; 1998 Sep; 72(9):7501-9. PubMed ID: 9696847
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A formalin inactivated whole SIVmac vaccine in Ribi adjuvant protects against homologous and heterologous SIV challenge.
    Putkonen P; Thorstensson R; Cranage M; Nilsson C; Ghavamzadeh L; Albert J; Greenaway P; Biberfeld G
    J Med Primatol; 1992; 21(2-3):108-12. PubMed ID: 1433260
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improved protection against simian immunodeficiency virus mucosal challenge in macaques primed with a DNA vaccine and boosted with the recombinant modified vaccinia virus Ankara and recombinant Semliki Forest virus.
    Martinon F; Brochard P; Ripaux M; Delache B; Aurégan G; Vaslin B; Le Grand R
    Vaccine; 2008 Jan; 26(4):532-45. PubMed ID: 18093703
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanisms of protection induced by attenuated simian immunodeficiency virus. I. Protection cannot be transferred with immune serum.
    Almond N; Rose J; Sangster R; Silvera P; Stebbings R; Walker B; Stott EJ
    J Gen Virol; 1997 Aug; 78 ( Pt 8)():1919-22. PubMed ID: 9266988
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protection against SIV infection in macaques by immunization with inactivated virus from the BK28 molecular clone, but not with BK28-derived recombinant env and gag proteins.
    Mills KH; Page M; Chan WL; Kitchin P; Stott EJ; Taffs F; Jones W; Rose J; Ling C; Silvera P
    J Med Primatol; 1992; 21(2-3):50-8. PubMed ID: 1433267
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protection of macaques against simian immunodeficiency virus infection with inactivated vaccines: comparison of adjuvants, doses and challenge viruses. The European Concerted Action on 'Macaque Models for AIDS Research'.
    Vaccine; 1995 Feb; 13(3):295-300. PubMed ID: 7631516
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Repeated exposure of rhesus macaques to low doses of simian immunodeficiency virus (SIV) did not protect them against the consequences of a high-dose SIV challenge.
    Dittmer U; Stahl-Hennig C; Coulibaly C; Nisslein T; Lüke W; Fuchs D; Bodemer W; Petry H; Hunsmann G
    J Gen Virol; 1995 Jun; 76 ( Pt 6)():1307-15. PubMed ID: 7782761
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vaccine protection against SIVmac infection by high- but not low-dose whole inactivated virus immunogen.
    Hartung S; Norley SG; Ennen J; Cichutek K; Plesker R; Kurth R
    J Acquir Immune Defic Syndr (1988); 1992; 5(5):461-8. PubMed ID: 1560342
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intrarectal challenge of macaques vaccinated with formalin-inactivated simian immunodeficiency virus.
    Cranage MP; Baskerville A; Ashworth LA; Dennis M; Cook N; Sharpe S; Farrar G; Rose J; Kitchin PA; Greenaway PJ
    Lancet; 1992 Feb; 339(8788):273-4. PubMed ID: 1346285
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Passive immunization of rhesus macaques against SIV infection and disease.
    Gardner M; Rosenthal A; Jennings M; Yee J; Antipa L; Robinson E
    AIDS Res Hum Retroviruses; 1995 Jul; 11(7):843-54. PubMed ID: 7546912
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of protection from homologous cell-free vs cell-associated SIV challenge afforded by inactivated whole SIV vaccines.
    Heeney JL; de Vries P; Dubbes R; Koornstra W; Niphuis H; ten Haaft P; Boes J; Dings ME; Morein B; Osterhaus AD
    J Med Primatol; 1992; 21(2-3):126-30. PubMed ID: 1433263
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of protection afforded by whole virus ISCOM versus MDP adjuvanted formalin-inactivated SIV vaccines from IV cell-free or cell-associated homologous challenge.
    Osterhaus A; de Vries P; Morein B; Akerblom L; Heeney J
    AIDS Res Hum Retroviruses; 1992 Aug; 8(8):1507-10. PubMed ID: 1466991
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vaccine-induced virus-neutralizing antibodies and cytotoxic T cells do not protect macaques from experimental infection with simian immunodeficiency virus SIVmac32H (J5).
    Hulskotte EG; Geretti AM; Siebelink KH; van Amerongen G; Cranage MP; Rud EW; Norley SG; de Vries P; Osterhaus AD
    J Virol; 1995 Oct; 69(10):6289-96. PubMed ID: 7666529
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunization with tween-ether-treated SIV adsorbed onto aluminum hydroxide protects monkeys against experimental SIV infection.
    Stahl-Hennig C; Voss G; Nick S; Petry H; Fuchs D; Wachter H; Coulibaly C; Lüke W; Hunsmann G
    Virology; 1992 Feb; 186(2):588-96. PubMed ID: 1733103
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.